1 – 3 of 3
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2020
-
Mark
Prognostic and predictive performance of R-ISS with SKY92 in older patients with multiple myeloma : The HOVON-87/NMSG-18 trial
- Contribution to journal › Article
-
Mark
Health-related quality of life in transplant ineligible newly diagnosed multiple myeloma patients treated with either thalidomide or lenalidomide-based regimen until progression : A prospective, open-label, multicenter, randomized, phase 3 study
Nielsen, Lene Kongsgaard ; Stege, Claudia ; Lissenberg-Witte, Birgit ; Der Holt, Bronno Van ; Mellqvist, Ulf Henrik ; Salomo, Morten ; Bos, Gerard ; Levin, Mark David ; Visser-Wisselaar, Heleen and Hansson, Markus LU
, et al.
(2020)
In Haematologica
105(6).
p.1650-1659
- Contribution to journal › Article
- 2016
-
Mark
Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma.
Zweegman, Sonja ; van der Holt, Bronno ; Mellqvist, Ulf-Henrik ; Salomo, Morten ; Bos, Gerard M J ; Levin, Mark-David ; Visser-Wisselaar, Heleen ; Hansson, Markus LU
; van der Velden, Annette W G
and Deenik, Wendy
, et al.
(2016)
In Blood
127(9).
p.1109-1116
- Contribution to journal › Article